{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:09:08Z","timestamp":1787890148826,"version":"build-2784847793"},"reference-count":71,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Some patients with metastatic castration\u2010resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic>. Tumors with <jats:italic>BRCA<\/jats:italic> mutations exhibit sensitivity to poly\u2010ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with <jats:italic>BRCA<\/jats:italic> mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC. There are practical challenges in the current molecular testing pathway in Australia that can compromise testing success. Testing success is often contingent on quality of tissue handling and laboratory processing techniques to minimize DNA degradation and suboptimal sequencing data quality. Greater adoption of best testing practices in Australia can be facilitated with education and greater awareness of expert recommendations. Here, we provide expert recommendations on how to optimize <jats:italic>BRCA<\/jats:italic> molecular diagnostic testing in patients with mCRPC. Optimization and standardization of molecular diagnostic testing will support health care providers and institutes in establishing more efficient testing pathways, enabling access to targeted therapies such as PARPi, and improving patient outcomes.<\/jats:p>","DOI":"10.1111\/ajco.14150","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T10:03:19Z","timestamp":1737194599000},"page":"345-358","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["<i>BRCA<\/i> Mutation Testing in Men With Metastatic Castration\u2010Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice"],"prefix":"10.1111","volume":"21","author":[{"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Peter MacCallum Cancer Centre  Parkville Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Parkville Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-5261","authenticated-orcid":false,"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Health and Human Sciences Macquarie University Westmead Hospital  Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley","family":"Campbell","sequence":"additional","affiliation":[{"name":"Austin Health Clinical Genetics Department  Heidelberg Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Care Services Royal Brisbane &amp; Women's Hospital  Herston Queensland Australia"},{"name":"Department of Faculty of Health Queensland University of Technology  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Rathi","sequence":"additional","affiliation":[{"name":"LifeStrands Genomics Australia Mount Waverley  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"EAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010SIOG Guidelines on Prostate Cancer 2023","author":"Mottet N.","year":"2023"},{"issue":"12","key":"e_1_2_6_3_1","first-page":"1288","article-title":"NCCN GUIDELINES\u00ae INSIGHTS: Prostate Cancer, Version 1.2023: Featured Updates to the NCCN Guidelines","volume":"20","author":"Schaeffer E. M. S. S.","year":"2022","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.203"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092435"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.07.001"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_2_6_9_1","unstructured":"eviQ.Advanced metastatic or recurrent olaparib (ID: 3737 v.3).2023."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"e_1_2_6_13_1","volume-title":"Guidelines for Genetic Testing in Prostate Cancer: A Scoping Review","author":"Tuffaha H.","year":"2023"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0931"},{"key":"e_1_2_6_15_1","volume-title":"Medicare Benefits Schedule Online"},{"key":"e_1_2_6_16_1","unstructured":"Medicare Benefits Schedule\u2014Item 73303: Australian Government\u2010 Department of Health and Aged Care 2023) https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73303&qt=ItemID."},{"key":"e_1_2_6_17_1","unstructured":"Medicare Benefits Schedule\u2014Item 73304: Australian Government\u2010 Department of Health and Aged Care 2023 https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73304&qt=item."},{"key":"e_1_2_6_18_1","unstructured":"Medicare Benefits Schedule\u2014Item 73302: Australian Government\u2010 Department of Health and Aged Care 2023 https:\/\/www9.health.gov.au\/mbs\/fullDisplay.cfm?type=item&q=73302&qt=item."},{"key":"e_1_2_6_19_1","volume-title":"Germline Testing in Individuals for Whom BRCA1 and BRCA2 Tumour Testing May Inform Systemic Therapy Options (ID: 4251 v.1)","author":"eviQ","year":"2023"},{"key":"e_1_2_6_20_1","unstructured":"eviQ.Prostate cancer\u2014panel testing (ID: 3648 v.4) 2023 https:\/\/www.eviq.org.au\/cancer\u2010genetics\/adult\/genetic\u2010testing\u2010using\u2010cancer\u2010gene\u2010panels\/3648\u2010prostate\u2010cancer\u2010panel\u2010testing."},{"key":"e_1_2_6_21_1","volume-title":"Considerations for Germline Testing for Variants Identified in Solid Tumours (ID: 4056 v.1)","author":"eviQ","year":"2023"},{"key":"e_1_2_6_22_1","unstructured":"A.Genomics National clinical consent forms https:\/\/www.australiangenomics.org.au\/tools\u2010and\u2010resources\/national\u2010clinical\u2010consent\u2010forms\/."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2012.32.1.5"},{"key":"e_1_2_6_24_1","volume-title":"Requirements for Medical Testing for Human Genetic Variation (Third Edition)","author":"Australian Commission on Safety and Quality in Health Care","year":"2022"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28015"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3940"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0691-RA"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0044-SA.1"},{"issue":"168","key":"e_1_2_6_30_1","first-page":"1","article-title":"A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers\u2010Specimens of Low Tumor Percentage Should Be Analyzed with Caution","volume":"14","author":"Zarabi S. K.","year":"2024","journal-title":"Biomolecules"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1219-x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21812"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.100901"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3940"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.10.002"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.11.002"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122030"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq661"},{"key":"e_1_2_6_39_1","unstructured":"eviQ.Guide for health professionals ordering genetic testing (ID: 3751 v.3) 2023 https:\/\/www.eviq.org.au\/cancer\u2010genetics\/resources\/3751\u2010guide\u2010for\u2010health\u2010professionals\u2010ordering\u2010genet#resources."},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz136"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-021-00261-1"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13334"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2016.25.12.690"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100459"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-018-0413-5"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133272"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054497"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000655"},{"issue":"99","key":"e_1_2_6_49_1","first-page":"1","article-title":"Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer","volume":"12","author":"Duffy M. J.","year":"2022","journal-title":"Journal of Personalized Medicine"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104738"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.044"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00424"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3577"},{"key":"e_1_2_6_54_1","volume-title":"PROpel: Phase III Trial of Olaparib (ola) and Abiraterone versus Placebo and Abi as First\u2010line Therapy for Patients with Metastatic Castration\u2010resistant Prostate Cancer (mCRPC)","author":"Saad F.","year":"2022"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1502"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.012"},{"key":"e_1_2_6_57_1","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration\u2010Resistant Prostate Cancer","author":"Chi K. N.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA17"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11125"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx118"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043"},{"key":"e_1_2_6_62_1","volume-title":"Therapeutic Goods Administration\u2010Australian Government","author":"TGA. LYNPARZA (AstraZeneca Pty Ltd)","year":"2023"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132031"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.18"},{"key":"e_1_2_6_69_1","volume-title":"A Clinical Study Evaluating the Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant to Testosterone\u2010Deprivation Therapy (CASPAR)","author":"NIH","year":"2023"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00757-9"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00376-4"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01055-3"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:43:56Z","timestamp":1754905436000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/ajco.14150"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14150","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"2024-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}